Tag Archive for: Collaboration

DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product

/in

Turku, Finland – 28 March 2022: – DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Optifye Therapeutics AG, a Swiss-based pharmaceutical company focusing on the development and commercialization of treatments for ophthalmic indications, today announced an exclusive licensing agreement pertaining to the development of controlled-release dexamethasone eye drops utilizing DelSiTech™ Silica Matrix technology. Read more…

Read more

Futura Announces Collaboration with Menarini Korea to Commercialise MED3000 in South Korea

/in

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into a licensing agreement with A. Menarini Korea Limited (“Menarini Korea”), a wholly owned subsidiary of Menarini Group, for […]

Read more

Biocomposites signs agreement with Zimmer Biomet to distribute new genex Bone Graft Substitute

/in

genex Bone Graft Substitute upgraded with a new closed-mixing system and a comprehensive set of delivery options for U.S. marketZimmer Biomet will exclusively distribute genex Bone Graft Substitute in the U.S. Keele, UK, 22 March 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing […]

Read more

Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie

/in

March 1, 2022 Deal value of US$ 1 billion with US$ 130 million upfront Novo Holdings co-created Syndesi Therapeutics in partnership with UCB Pharma and co-led the Series A financing Syndesi’s lead program SDI-118 to be accelerated by AbbVie to the benefit of patients suffering from cognitive impairment associated with a range of neurodegenerative and […]

Read more

Genmab and Synaffix Enter into License Agreement for ADC Technology

/in

Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus […]

Read more